oral semaglutide novo nordisk novonordisk has received European Commission approval for Wegovy® pill, the European Union's first GLP-1 receptor agonist for chronic weight management. The once-daily oral is approved for adults with obesity or Novo Nordisk on X: "#PRESS

Glutathione plays an important role in protecting the cells from oxidative stress and supporting immune function

Bit of Background These new classes of antiobesity medications (ie, the GLP-1 agonists and dual agonists), referred to in this article as weight management medications, arent really new.1-4 The basic science and pharmaceutical research and development to bring these to market began more than two decades ago when two scientists, Matthias Tschop, MD, and Richard DiMarchi, PhD, hypothesized that the actions of various gut hormones may offer safe and unprecedented weight loss

National Diabetes Statistics Report, 2017: Estimates of Diabetes and Its Burden in the United States

View price-match criteria Same medication & dosage Must be the same active ingredient, formulation, dose, and total quantity